CN106660987B - 赖氨酸特异性脱甲基酶-1的抑制剂 - Google Patents

赖氨酸特异性脱甲基酶-1的抑制剂 Download PDF

Info

Publication number
CN106660987B
CN106660987B CN201580046216.4A CN201580046216A CN106660987B CN 106660987 B CN106660987 B CN 106660987B CN 201580046216 A CN201580046216 A CN 201580046216A CN 106660987 B CN106660987 B CN 106660987B
Authority
CN
China
Prior art keywords
oxo
methyl
benzonitrile
amino
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201580046216.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN106660987A (zh
Inventor
扬·K·陈
陶菲克·卡努尼
杰弗里·艾伦·斯塔福德
詹姆斯·马文·维尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Quanticel Research Inc
Original Assignee
Quanticel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54938856&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN106660987(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Quanticel Pharmaceuticals Inc filed Critical Quanticel Pharmaceuticals Inc
Publication of CN106660987A publication Critical patent/CN106660987A/zh
Application granted granted Critical
Publication of CN106660987B publication Critical patent/CN106660987B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polyamides (AREA)
CN201580046216.4A 2014-06-27 2015-06-26 赖氨酸特异性脱甲基酶-1的抑制剂 Expired - Fee Related CN106660987B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462018365P 2014-06-27 2014-06-27
US62/018,365 2014-06-27
PCT/US2015/038089 WO2015200843A1 (en) 2014-06-27 2015-06-26 Inhibitors of lysine specific demethylase-1

Publications (2)

Publication Number Publication Date
CN106660987A CN106660987A (zh) 2017-05-10
CN106660987B true CN106660987B (zh) 2020-11-06

Family

ID=54938856

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580046216.4A Expired - Fee Related CN106660987B (zh) 2014-06-27 2015-06-26 赖氨酸特异性脱甲基酶-1的抑制剂

Country Status (28)

Country Link
US (3) US10011583B2 (enExample)
EP (1) EP3160956B1 (enExample)
JP (2) JP6587241B2 (enExample)
KR (1) KR102438302B1 (enExample)
CN (1) CN106660987B (enExample)
AU (2) AU2015279591A1 (enExample)
BR (1) BR112016030697B1 (enExample)
CA (1) CA2953810C (enExample)
CL (1) CL2016003350A1 (enExample)
CO (1) CO2017000362A2 (enExample)
CY (1) CY1123475T1 (enExample)
DK (1) DK3160956T3 (enExample)
EA (1) EA030946B1 (enExample)
EC (1) ECSP17005635A (enExample)
ES (1) ES2812626T3 (enExample)
HR (1) HRP20201337T1 (enExample)
HU (1) HUE050564T2 (enExample)
IL (1) IL249733B (enExample)
LT (1) LT3160956T (enExample)
MX (1) MX376632B (enExample)
PL (1) PL3160956T3 (enExample)
PT (1) PT3160956T (enExample)
RS (1) RS60658B1 (enExample)
SG (2) SG11201610866PA (enExample)
SI (1) SI3160956T1 (enExample)
SM (1) SMT202000443T1 (enExample)
WO (1) WO2015200843A1 (enExample)
ZA (1) ZA201700069B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015021128A1 (en) 2013-08-06 2015-02-12 Imago Biosciences Inc. Kdm1a inhibitors for the treatment of disease
LT3160956T (lt) 2014-06-27 2020-09-10 Celgene Quanticel Research, Inc. Lizinui specifinės demetilazės-1 inhibitoriai
MX395534B (es) * 2014-07-03 2025-03-25 Celgene Quanticel Res Inc Inhibidores de demetilasa-1 especifica de lisina.
HRP20250119T1 (hr) 2015-02-12 2025-03-28 Imago Biosciences Inc. Kdm1a inhibitor i njegova primjena u terapiji
CA2987876A1 (en) 2015-06-12 2016-12-15 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
WO2017013061A1 (en) 2015-07-17 2017-01-26 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
EA201892075A1 (ru) 2016-03-15 2019-04-30 Оризон Дженомикс, С.А. Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей
US11034991B2 (en) 2016-03-16 2021-06-15 Oryzon Genomics S.A. Methods to determine KDM1A target engagement and chemoprobes useful therefor
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
CN111194306B (zh) 2016-08-16 2023-05-16 伊美格生物科学公司 用于制备kdm1a抑制剂的方法和过程
WO2018083189A1 (en) 2016-11-03 2018-05-11 Oryzon Genomics, S.A. Biomarkers for determining responsiveness to lsd1 inhibitors
JP7089506B2 (ja) * 2017-04-10 2022-06-22 三井化学アグロ株式会社 ピリドン化合物を有効成分として含有する抗真菌剤およびその使用方法
JP2020121925A (ja) * 2017-04-10 2020-08-13 三井化学アグロ株式会社 ピリドン化合物とキノリン系化合物を含有する有害生物防除組成物および有害生物の防除方法、ならびに新規キノリン系化合物
JP7071962B2 (ja) * 2017-04-10 2022-05-19 三井化学アグロ株式会社 ピリドン化合物と有害生物防除剤を含有する有害生物防除組成物および有害生物の防除方法
LT3661510T (lt) 2017-08-03 2025-01-27 Oryzon Genomics, S.A. Elgesio pakitimų gydymo būdai
CN112368272B (zh) * 2018-03-21 2023-04-21 苏州浦合医药科技有限公司 Shp2抑制剂及其用途
US11578059B2 (en) * 2018-05-11 2023-02-14 Imago Biosciences. Inc. KDM1A inhibitors for the treatment of disease
CN120837494A (zh) 2019-03-20 2025-10-28 奥莱松基因组股份有限公司 使用kdm1a抑制剂如化合物伐菲德司他治疗注意缺陷多动症的方法
SG11202109159VA (en) 2019-03-20 2021-10-28 Oryzon Genomics Sa Methods of treating borderline personality disorder
WO2021004610A1 (en) 2019-07-05 2021-01-14 Oryzon Genomics, S.A. Biomarkers and methods for personalized treatment of small cell lung cancer using kdm1a inhibitors
KR20230167102A (ko) 2021-04-08 2023-12-07 오리존 지노믹스 에스.에이. 골수성 암 치료를 위한 lsd1 억제제의 조합물
EP4419504A4 (en) * 2021-10-18 2025-09-03 Imago Biosciences Inc KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE
JP2025516648A (ja) 2022-05-09 2025-05-30 オリゾン・ゲノミクス・ソシエダッド・アノニマ Lsd1阻害薬を用いるnf1変異腫瘍の治療法
WO2023217758A1 (en) 2022-05-09 2023-11-16 Oryzon Genomics, S.A. Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors
WO2024110649A1 (en) 2022-11-24 2024-05-30 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2599925A1 (en) * 2005-03-14 2006-09-21 Merck & Co., Inc. Cgrp receptor antagonists
US20090186907A1 (en) * 2006-06-21 2009-07-23 E.I. Dupont De Nemours And Company Pyrazinones As Cellular Proliferation Inhibitors
BRPI0813244B8 (pt) * 2007-06-27 2021-05-25 Astrazeneca Ab compostos derivados de pirazinona, composições compreendendo ditos compostos, uso dos compostos no tratamento de doenças de pulmão e composto intermediário
CL2008002793A1 (es) * 2007-09-20 2009-09-04 Cgi Pharmaceuticals Inc Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
US9006449B2 (en) * 2010-07-29 2015-04-14 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as LSD1 inhibitors
WO2013185284A1 (en) * 2012-06-12 2013-12-19 Abbott Laboratories Pyridinone and pyridazinone derivatives
JP6430512B2 (ja) 2013-12-11 2018-11-28 セルジーン クオンティセル リサーチ,インク. リジン特異的デメチラーゼ−1の阻害剤
CN103804312B (zh) * 2014-02-17 2016-04-20 四川百利药业有限责任公司 一类氮杂环化合物及其制备方法和用途
SI3137169T1 (sl) * 2014-05-01 2022-04-29 Celgene Quanticel Research, Inc. Inhibitorji lizin specifične demetilaze-1
LT3160956T (lt) 2014-06-27 2020-09-10 Celgene Quanticel Research, Inc. Lizinui specifinės demetilazės-1 inhibitoriai

Also Published As

Publication number Publication date
CA2953810C (en) 2022-07-12
EP3160956A1 (en) 2017-05-03
CL2016003350A1 (es) 2018-05-11
BR112016030697B1 (pt) 2023-03-21
MX376632B (es) 2025-03-07
LT3160956T (lt) 2020-09-10
AU2015279591A1 (en) 2017-01-19
WO2015200843A1 (en) 2015-12-30
HUE050564T2 (hu) 2020-12-28
ES2812626T3 (es) 2021-03-17
KR102438302B1 (ko) 2022-08-30
JP2017519781A (ja) 2017-07-20
US20200172506A1 (en) 2020-06-04
EP3160956A4 (en) 2018-01-10
EA201692513A1 (ru) 2017-05-31
CA2953810A1 (en) 2015-12-30
JP6587241B2 (ja) 2019-10-09
US10011583B2 (en) 2018-07-03
RS60658B1 (sr) 2020-09-30
PL3160956T3 (pl) 2020-11-30
CO2017000362A2 (es) 2017-04-10
MX2017000179A (es) 2017-05-01
PT3160956T (pt) 2020-09-01
ZA201700069B (en) 2018-04-25
AU2019261771B2 (en) 2020-09-24
CN106660987A (zh) 2017-05-10
JP6851418B2 (ja) 2021-03-31
US11028066B2 (en) 2021-06-08
HRP20201337T1 (hr) 2020-11-27
US20180273505A1 (en) 2018-09-27
US20170137402A1 (en) 2017-05-18
SMT202000443T1 (it) 2020-09-10
IL249733A0 (en) 2017-02-28
IL249733B (en) 2020-07-30
AU2019261771A1 (en) 2019-11-28
CY1123475T1 (el) 2022-03-24
SG11201610866PA (en) 2017-01-27
JP2019167345A (ja) 2019-10-03
SG10201911220TA (en) 2020-02-27
KR20170018913A (ko) 2017-02-20
ECSP17005635A (es) 2017-03-31
SI3160956T1 (sl) 2020-11-30
EP3160956B1 (en) 2020-05-27
US10597376B2 (en) 2020-03-24
EA030946B1 (ru) 2018-10-31
BR112016030697A2 (pt) 2018-07-17
DK3160956T3 (da) 2020-08-31

Similar Documents

Publication Publication Date Title
CN106660987B (zh) 赖氨酸特异性脱甲基酶-1的抑制剂
JP6768857B2 (ja) リジン特異的なデメチラーゼ−1の阻害剤
CN106659914B (zh) 赖氨酸特异性脱甲基酶-1的抑制剂
JP6692350B2 (ja) リジン特異的なデメチラーゼ−1の阻害剤
CN106604997B (zh) 赖氨酸特异性脱甲基酶-1的抑制剂
HK1231860A1 (en) Inhibitors of lysine specific demethylase-1
HK1231860B (en) Inhibitors of lysine specific demethylase-1
HK1235332A1 (en) Inhibitors of lysine specific demethylase-1

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20201106

CF01 Termination of patent right due to non-payment of annual fee